Bridgebio Oncology Therapeutics revenue was $0.00 for the trailing 12 months ending Jun 30, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q2 2025) ending on Jun 30, 2025 was $0.0, down N/A from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, BBOT annual revenue was $0.0, with N/A growth year-over-year.
BBOT revenue history
Current Revenue
$0.0
Current Earnings
-$106.5M
Current Profit Margin
0%
Be the first to know when BBOT announces revenue.
BBOT Revenue History By Year
BBOT Yearly Revenue
BBOT Revenue
BBOT Change
BBOT Revenue Growth
2024-12-31
$0.00
N/A
N/A
2023-12-31
$0.00
N/A
N/A
2022-12-31
$0.00
N/A
N/A
1 of 1
Bridgebio Oncology Therapeutics Revenue FAQ
What was BBOT's revenue last quarter?
On Invalid Date, Bridgebio Oncology Therapeutics (NASDAQ: BBOT) reported Q2 2025 revenue of $0.00 up N/A year over year. In the same quarter last year, Bridgebio Oncology Therapeutics's revenue was $0.00.
What was Bridgebio Oncology Therapeutics's revenue in 2024?
Bridgebio Oncology Therapeutics's annual revenue for the twelve months ending Dec 31, 2024 was $0.00, a N/A decrease year over year.
How much does Bridgebio Oncology Therapeutics make in a day?
Based on Bridgebio Oncology Therapeutics annual revenue for the past two years, BBOT makes an average of $0.00 per day.
What was Bridgebio Oncology Therapeutics's annual revenue growth in the past year?
As of Q3 2025, Bridgebio Oncology Therapeutics's revenue has grown null year over year. Bridgebio Oncology Therapeutics's revenue in the past year totaled $0.00.
How much does Bridgebio Oncology Therapeutics make in a year?
Bridgebio Oncology Therapeutics's revenue by year for the past two years is:
Bridgebio Oncology Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $0.00, a N/A decrease year over year.
Bridgebio Oncology Therapeutics's annual revenue for Dec 31, 2023 was $0.00, a N/A decrease from 2022.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.